{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:44:00Z","timestamp":1791996240757,"version":"4.4.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02708-2","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T08:55:02Z","timestamp":1778057702000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Sintilimab (PD-1 inhibitor) plus lenvatinib as conversion therapy followed by sequential surgery (SILENSES) for advanced unresectable hepatocellular carcinoma: a phase II, expansion trial"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-7444-734X","authenticated-orcid":false,"given":"Shichun","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenwen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junfeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingyang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuerui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinbiao","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanbo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiyi","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baolin","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangyu","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinzhe","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haowen","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liru","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiqing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangbing","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"key":"2708_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J. Clin. 74, 229\u2013263 (2024).","journal-title":"CA: A Cancer J. Clin."},{"key":"2708_CR2","unstructured":"European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma. J. Hepatol. 82, 315\u2013374 (2025)."},{"key":"2708_CR3","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41575-022-00704-9","volume":"20","author":"C Yang","year":"2023","unstructured":"Yang, C. et al. Evolving therapeutic landscape of advanced hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol. 20, 203\u2013222 (2023).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"2708_CR4","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","volume":"76","author":"A-L Cheng","year":"2022","unstructured":"Cheng, A.-L. et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J. Hepatol. 76, 862\u2013873 (2022).","journal-title":"J. Hepatol."},{"key":"2708_CR5","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn, R. S. et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N. Engl. J. Med. 382, 1894\u20131905 (2020).","journal-title":"N. Engl. J. Med."},{"key":"2708_CR6","doi-asserted-by":"crossref","unstructured":"Kudo, M. et al. Updated efficacy and safety of KEYNOTE-224: A phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib. Eur. J. Cancer (Oxford, England : 1990) 167(2022).","DOI":"10.1016\/j.ejca.2022.02.009"},{"key":"2708_CR7","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.1200\/JCO.20.00808","volume":"38","author":"RS Finn","year":"2020","unstructured":"Finn, R. S. et al. Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. J. Clin. Oncol. 38, 2960\u20132970 (2020).","journal-title":"J. Clin. Oncol."},{"key":"2708_CR8","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1136\/gutjnl-2019-320116","volume":"69","author":"Z Feng","year":"2020","unstructured":"Feng, Z., Rong, P. & Wang, W. Meta-analysis of the efficacy and safety of PD-1\/PD-L1 inhibitors administered alone or in combination with anti-VEGF agents in advanced hepatocellular carcinoma. Gut 69, 1904\u20131906 (2020).","journal-title":"Gut"},{"key":"2708_CR9","doi-asserted-by":"publisher","first-page":"e22782","DOI":"10.1097\/MD.0000000000022782","volume":"99","author":"T Tomonari","year":"2020","unstructured":"Tomonari, T. et al. Conversion therapy for unresectable hepatocellular carcinoma after lenvatinib: Three case reports. Medicine 99, e22782 (2020).","journal-title":"Medicine"},{"key":"2708_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-12772-y","volume":"24","author":"H Xu","year":"2024","unstructured":"Xu, H., Zhang, H., Li, B., Chen, K. & Wei, Y. Systemic conversion therapies for initially unresectable hepatocellular carcinoma: A systematic review and meta-analysis. BMC Cancer 24, 1008 (2024).","journal-title":"BMC Cancer"},{"key":"2708_CR11","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1111\/cas.16194","volume":"115","author":"M-D Wang","year":"2024","unstructured":"Wang, M.-D. et al. Conversion therapy for advanced hepatocellular carcinoma in the era of precision medicine: Current status, challenges and opportunities. Cancer Sci. 115, 2159\u20132169 (2024).","journal-title":"Cancer Sci."},{"key":"2708_CR12","doi-asserted-by":"crossref","unstructured":"Zhang, W. et al. Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial. J. Immunother. Cancer 11, e007366 (2023).","DOI":"10.1136\/jitc-2023-007366"},{"key":"2708_CR13","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1016\/S1470-2045(24)00457-1","volume":"25","author":"A D\u2019Alessio","year":"2024","unstructured":"D\u2019Alessio, A. et al. Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: A cross-trial, patient-level analysis. Lancet Oncol. 25, 1465\u20131475 (2024).","journal-title":"Lancet Oncol."},{"key":"2708_CR14","doi-asserted-by":"publisher","first-page":"525","DOI":"10.5582\/bst.2024.01372","volume":"18","author":"H Hakoda","year":"2025","unstructured":"Hakoda, H., Ichida, A. & Hasegawa, K. Advances in systemic therapy leading to conversion surgery for advanced hepatocellular carcinoma. Biosci. Trends 18, 525\u2013534 (2025).","journal-title":"Biosci. Trends"},{"key":"2708_CR15","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","volume":"22","author":"Z Ren","year":"2021","unstructured":"Ren, Z. et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): A randomised, open-label, phase 2-3 study. Lancet Oncol. 22, 977\u2013990 (2021).","journal-title":"Lancet Oncol."},{"key":"2708_CR16","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1097\/HEP.0000000000000776","volume":"80","author":"M Zhu","year":"2024","unstructured":"Zhu, M. et al. Sintilimab plus bevacizumab combined with radiotherapy as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A multicenter, single-arm, phase 2 study. Hepatol. (Baltim., Md.) 80, 807\u2013815 (2024).","journal-title":"Hepatol. (Baltim., Md.)"},{"key":"2708_CR17","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0140-6736(24)02575-3","volume":"405","author":"M Kudo","year":"2025","unstructured":"Kudo, M. et al. Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): A multicentre, randomised, double-blind, phase 3 study. Lancet (Lond., Engl.) 405, 203\u2013215 (2025).","journal-title":"Lancet (Lond., Engl.)"},{"key":"2708_CR18","doi-asserted-by":"publisher","first-page":"v286","DOI":"10.1093\/annonc\/mdz247.073","volume":"30","author":"J Llovet","year":"2019","unstructured":"Llovet, J. et al. A phase Ib trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): updated results. Ann. Oncol. 30, v286\u2013v287 (2019).","journal-title":"Ann. Oncol."},{"key":"2708_CR19","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1111\/liv.15831","volume":"44","author":"M Cai","year":"2024","unstructured":"Cai, M. et al. Lenvatinib, sintilimab plus transarterial chemoembolization for advanced stage hepatocellular carcinoma: A phase II study. Liver Int. 44, 920\u2013930 (2024).","journal-title":"Liver Int."},{"key":"2708_CR20","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/S1470-2045(23)00469-2","volume":"24","author":"JM Llovet","year":"2023","unstructured":"Llovet, J. M. et al. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): A randomised, double-blind, phase 3 trial. Lancet Oncol. 24, 1399\u20131410 (2023).","journal-title":"Lancet Oncol."},{"key":"2708_CR21","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41392-025-02333-5","volume":"10","author":"C Zhao","year":"2025","unstructured":"Zhao, C. et al. Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: A randomized phase 2\/3 trial. Signal Transduct. Target Ther. 10, 249 (2025).","journal-title":"Signal Transduct. Target Ther."},{"key":"2708_CR22","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jhep.2022.09.006","volume":"78","author":"M Kudo","year":"2023","unstructured":"Kudo, M. et al. Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study. J. Hepatol. 78, 133\u2013141 (2023).","journal-title":"J. Hepatol."},{"key":"2708_CR23","doi-asserted-by":"publisher","first-page":"S656","DOI":"10.1016\/j.annonc.2024.08.1007","volume":"35","author":"L Rimassa","year":"2024","unstructured":"Rimassa, L. et al. 947MO Five-year overall survival (OS) and OS by tumour response measures from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC). Ann. Oncol. 35, S656 (2024).","journal-title":"Ann. Oncol."},{"key":"2708_CR24","doi-asserted-by":"publisher","first-page":"472","DOI":"10.21037\/hbsn-22-527","volume":"13","author":"H Wang","year":"2024","unstructured":"Wang, H., Qian, Y.-W., Dong, H. & Cong, W.-M. Pathologic assessment of hepatocellular carcinoma in the era of immunotherapy: A narrative review. Hepatobiliary Surg. Nutr. 13, 472\u2013493 (2024).","journal-title":"Hepatobiliary Surg. Nutr."},{"key":"2708_CR25","doi-asserted-by":"publisher","first-page":"4060","DOI":"10.1200\/JCO.24.00645","volume":"42","author":"Y-C Shen","year":"2024","unstructured":"Shen, Y.-C. et al. Clinical outcomes and histologic findings of patients with hepatocellular carcinoma with durable partial response or durable stable disease after receiving atezolizumab plus bevacizumab. J. Clin. Oncol. 42, 4060\u20134070 (2024).","journal-title":"J. Clin. Oncol."},{"key":"2708_CR26","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1097\/HEP.0000000000001026","volume":"81","author":"C Celsa","year":"2025","unstructured":"Celsa, C. et al. Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment. Hepatol. (Baltim., Md.) 81, 837\u2013852 (2025).","journal-title":"Hepatol. (Baltim., Md.)"},{"key":"2708_CR27","doi-asserted-by":"crossref","unstructured":"Guo, X. et al. Contrasting cytotoxic and regulatory T cell responses underlying distinct clinical outcomes to anti-PD-1 plus lenvatinib therapy in cancer. Cancer Cell 43, 248\u2013268.e9 (2025).","DOI":"10.1016\/j.ccell.2025.01.001"},{"key":"2708_CR28","first-page":"581","volume":"32","author":"Department of Medical Administration, N.H.C.o.t.P.s.R.o.C","year":"2024","unstructured":"Department of Medical Administration, N.H.C.o.t.P.s.R.o.C Guideline for diagnosis and treatment of primary liver cancer (2024 version). Chin. J. Hepatol. 32, 581\u2013630 (2024).","journal-title":"Chin. J. Hepatol."},{"key":"2708_CR29","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","volume":"112","author":"A Freites-Martinez","year":"2021","unstructured":"Freites-Martinez, A., Santana, N., Arias-Santiago, S. & Viera, A. Using the common terminology criteria for adverse events (CTCAE - Version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermo-sifiliograficas 112, 90\u201392 (2021).","journal-title":"Actas Dermo-sifiliograficas"},{"key":"2708_CR30","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/SLA.0b013e3181b13ca2","volume":"250","author":"PA Clavien","year":"2009","unstructured":"Clavien, P. A. et al. The Clavien-Dindo classification of surgical complications: Five-year experience. Ann. Surg. 250, 187\u2013196 (2009).","journal-title":"Ann. Surg."},{"key":"2708_CR31","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","volume":"30","author":"R Lencioni","year":"2010","unstructured":"Lencioni, R. & Llovet, J. M. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin. Liver Dis. 30, 52\u201360 (2010).","journal-title":"Semin. Liver Dis."},{"key":"2708_CR32","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","volume":"62","author":"LH Schwartz","year":"2016","unstructured":"Schwartz, L. H. et al. RECIST 1.1\u2014Update and clarification: From the RECIST committee. Eur. J. Cancer 62, 132\u2013137 (2016).","journal-title":"Eur. J. Cancer"}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02708-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02708-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02708-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T08:55:11Z","timestamp":1778057711000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02708-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,6]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2708"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02708-2","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,6]]},"assertion":[{"value":"25 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"167"}}